Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

Last updated: May 30, 2024
Sponsor: Proton Collaborative Group
Overall Status: Active - Recruiting

Phase

2

Condition

Breast Cancer

Cancer

Treatment

Proton Radiotherapy

Clinical Study ID

NCT01766297
BRE007-12
  • Ages > 50
  • Female

Study Summary

The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy.

This study is being done to see if proton radiation therapy will prove to be beneficial for women with early stage breast cancer. A clinical study is necessary to compare the results (good or bad) of proton radiation therapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Must sign study-specific, IRB approved informed consent form prior to study entry.Note consent by legally authorized representative is not allowed for this trial.

  • Must be female.

  • Must be > = 50 years of age.

  • Must have a life expectancy of at least 5 years based on age and co-morbidities.

  • Must have pathology proven invasive ductal carcinoma (lobular is not allowed) and/orductal carcinoma in situ (DCIS).

  • One of the following criteria must be met: (a) Tumors that are microscopicallymultifocal must be 3.0 cm or less in total aggregate size and encompassed within asingle scar (b) Patient does not have microscopically multifocal tumor.

  • For tumors that are invasive, if in the presence of extensive intraductal component (EIC), the entire pathologic tumor size (including both the intraductal and invasivecomponent) must be 3.0 cm or less.

  • Must be Stage 0, I, II (Tis, T1, or T2, N0, M0 per AJCC criteria 7th and/or 8thEd.). If stage II, the tumor size must be < = 3.0 cm. A patient with invasivehistology must have nodal stage pN0 by H&E stains on sentinel node biopsy oraxillary lymph node dissection.

  • Must have ER positive disease with ER/PR report available.

  • For tumors that are invasive, HER2 must be performed (positive or negative isacceptable).

  • Must have a lumpectomy performed, with documented negative surgical margins by 0.2cm or more. If re-excision results in negative surgical margins 0.2 cm or more,patient is eligible.

  • If image guidance with daily cone beam CT with direct physician visual assessment isused for treatment positioning, the presence of markers or clips in the surgical bedis recommended but not required. If cone beam CT imaging will NOT be used for imageguidance, then the patient must be prepared to have 2 fiducial markers minimum, 3preferred, placed prior to treatment (if not previously done).

  • If markers or clips were placed at the time of surgery, patient must be able tostart treatment within 12 weeks after lumpectomy or re-excision for adequatemargins.

  • If markers were not placed at the time of surgery and are needed, patient musthave markers placed within 6 weeks after surgery.

  • If systemic chemotherapy was given, patient must have had clips or markersplaced at the time of surgery (if they are needed) and patient must havesimulation scans within 6 weeks of the completion of the chemotherapy.

  • Must be able to start treatment within 12 weeks of surgery or 8 weeks offinalization of chemotherapy.

Exclusion

Exclusion Criteria:

  • Previous history of ipsilateral invasive breast cancer or DCIS.

  • Any clinical or radiographically suspicious nodes, unless biopsy proven benign.

  • Non-epithelial malignancies such as sarcoma or lymphoma.

  • Suspicious residual microcalcifications on mammography of either breast, unlessnegative for malignancy on pathology.

  • Multicentric or bilateral disease unless biopsy of the clinical abnormalities areperformed and result is negative.

  • Lymphovascular space invasion (LVSI) on pathology specimen.

  • Any previously treated breast carcinoma or synchronous breast carcinoma inipsilateral breast.

  • Prior radiation therapy to the ipsilateral breast or thorax.

  • Paget's disease of the nipple.

  • Histologic examination showing invasive lobular histology.

  • Skin involvement.

  • Breasts technically unsatisfactory for radiation treatment upon the discretion ofthe treating physician.

  • Significant infection or other co-existing medical condition that would precludeprotocol therapy such as pregnancy, HIV/AIDS or collagen vascular diseasesspecifically systemic lupus erythematosus, scleroderma, or dermatomyositis.

  • Known BRCA 1 or BRCA 2 mutation.

  • Pregnant or lactating.

Study Design

Total Participants: 132
Treatment Group(s): 1
Primary Treatment: Proton Radiotherapy
Phase: 2
Study Start date:
February 01, 2013
Estimated Completion Date:
January 31, 2033

Study Description

Current standard of care for early stage breast cancer is mastectomy or breast conserving therapy with whole breast irradiation following lumpectomy. However, studies of breast cancer recurrence have demonstrated the majority of tumors to recur in or adjacent to the original tumor site. The question has thus been raised as to whether radiation to the whole breast is necessary or justified. Limiting radiation to the area of the original tumor may reduce acute and long-term skin and organ toxicities while making radiation therapy more convenient and less expensive. Several clinical trials are underway comparing partial breast irradiation (PBI) to whole breast irradiation. Numerous centers are offering partial breast irradiation outside of clinical trials as well, despite the lack of long-term safety and efficacy data on PBI.

Available PBI methods include brachytherapy, in which catheters or balloons are surgically inserted to deliver radiation therapy to the lumpectomy cavity, and conventional external beam radiation therapy, or EBRT. External beam photon therapy is attractive for its non-invasive nature and ability to deliver a more homogenous dose distribution compared to brachytherapy, however it also delivers a greater radiation dose to surrounding normal breast tissue.Proton therapy has the capacity to provide the same advantages as photon EBRT while minimizing dose to normal surrounding tissue. Clinical data on PBI with protons is minimal, however, leaving many questions unanswered. The impetus behind this protocol is to address these gaps by further investigating the feasibility, safety, and efficacy of proton therapy for partial breast irradiation.

Connect with a study center

  • California Protons Cancer Therapy Center

    San Diego, California 92121
    United States

    Active - Recruiting

  • Northwestern Medicine Chicago Proton Center

    Warrenville, Illinois 60555
    United States

    Active - Recruiting

  • Maryland Proton Treatment Center

    Baltimore, Maryland 21201
    United States

    Active - Recruiting

  • McLaren Proton Therapy Center

    Flint, Michigan 48532
    United States

    Active - Recruiting

  • New York Proton Center

    New York, New York 10035
    United States

    Active - Recruiting

  • Oklahoma Proton Center

    Oklahoma City, Oklahoma 73142
    United States

    Active - Recruiting

  • Inova Schar Cancer Institute

    Fairfax, Virginia 22031
    United States

    Active - Recruiting

  • Hampton University Proton Therapy Institute

    Hampton, Virginia 23666
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.